bexarotene has been researched along with vorinostat in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, GL; Chen, K; Sun, ZZ; Wang, J; Wang, LH; Wang, S; Wu, CF; Yang, JY; Zhao, M; Zheng, HL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bradley, B; Parker, SR | 1 |
| Scheinfeld, N | 1 |
| Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W | 1 |
| Goerdt, S; Klemke, CD | 1 |
| Farley-Loftus, R; Latkowski, JA; Mandal, R | 1 |
| Casto, BC; Pereira, MA | 1 |
| Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ | 1 |
| Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S | 1 |
| Geskin, L; Malone, DC | 1 |
| Christensen, LF; Cooper, KD; Ellis, A; Kord, H; Meyerson, H; Sharma, T | 1 |
| Ahmadu, C; Armstrong, N; Chalker, A; Duffy, S; Grimm, SE; Hiligsmann, M; Joore, MA; Kleijnen, J; Ryder, S; Syndikus, I; Wijnen, B; Witlox, W; Wolff, R | 1 |
6 review(s) available for bexarotene and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antineoplastic Agents; Bexarotene; Biopsy; Cost of Illness; Diphtheria Toxin; Foundations; Humans; Hydroxamic Acids; Interferons; Interleukin-2; Mechlorethamine; Mycosis Fungoides; Neoplasm Staging; Photopheresis; Phototherapy; Physical Examination; Radiotherapy; Recombinant Fusion Proteins; Retinoids; Self-Help Groups; Skin Care; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2006 |
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approval; Humans; Hydroxamic Acids; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat | 2007 |
Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cytokines; Dendritic Cells; Diphtheria Toxin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interleukin-2; Keratinocytes; Lymphoma, T-Cell; Macrophages; Mast Cells; Membrane Glycoproteins; NF-kappa B; Receptors, Chemokine; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat | 2008 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2014 |
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bexarotene; Cost-Benefit Analysis; Humans; Mycosis Fungoides; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sezary Syndrome; Skin Neoplasms; State Medicine; Technology; Technology Assessment, Biomedical; Vorinostat | 2022 |
1 trial(s) available for bexarotene and vorinostat
| Article | Year |
|---|---|
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Cell Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Retinoic Acid; Retinoid X Receptors; Tetrahydronaphthalenes; Transcription, Genetic; Vorinostat | 2012 |
7 other study(ies) available for bexarotene and vorinostat
| Article | Year |
|---|---|
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HeLa Cells; Histone Deacetylases; HL-60 Cells; Humans; Models, Molecular; Molecular Structure; Retinoid X Receptors; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2008 |
Poikilodermatous mycosis fungoides.
Topics: Acitretin; Antineoplastic Agents; Bexarotene; Female; Humans; Hydroxamic Acids; Hypopigmentation; Immunophenotyping; Interferon-alpha; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy; Vorinostat | 2010 |
Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Body Weight; Budesonide; Chemoprevention; Female; Hydroxamic Acids; Lung Neoplasms; Mice; Tetrahydronaphthalenes; Vorinostat | 2011 |
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Methotrexate; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat | 2018 |
CD30
Topics: Aged; Bexarotene; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Treatment Outcome; Vorinostat | 2021 |